Open AccessDeep molecular responses for treatment‐free remission in chronic myeloid leukemia
Author(s) -
Dulucq Stéphanie,
Mahon FrancoisXavier
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.801
Subject(s) - nilotinib , dasatinib , myeloid leukemia , imatinib , tyrosine kinase inhibitor , medicine , clinical trial , tyrosine kinase , oncology , cancer research , immunology , pharmacology , receptor , cancer
Several clinical trials have demonstrated that some patients with chronic myeloid leukemia in chronic phase (CML‐CP) who achieve sustained deep molecular responses on tyrosine kinase inhibitor (TKI) therapy can safely suspend therapy and attempt treatment‐free remission (TFR). Many TFR studies to date have enrolled imatinib‐treated patients; however, the feasibility of TFR following nilotinib or dasatinib has also been demonstrated. In this review, we discuss available data from TFR trials and what these data reveal about the molecular biology of TFR. With an increasing number of ongoing TFR clinical trials, TFR may become an achievable goal for patients with CML‐CP.